Antimicrobial Agents, Drug Adverse Reactions and Interactions, and Cancer

  • Ximena Millan
  • Victoria Muggia
  • Belinda Ostrowsky
Part of the Cancer Treatment and Research book series (CTAR, volume 161)


The intent of this chapter is to review the types of adverse drug reactions and interactions associated with antimicrobial agents, specifically in the setting of patients with malignancies. The initial sections will discuss categorizing and describing the mechanisms of adverse reactions and interactions. The later sections include a detailed discussion about adverse reactions and drug interactions associated with commonly used antibacterial, antiviral, and antifungal agents in this subpopulation. Where relevant, the clinical use and indication for the drugs will be reviewed. The antibacterial section will specifically address the emergence of antimicrobial resistance and drugs of last resort (newer agents, such as linezolid and daptomycin and novel uses of older previously retired agents, such as polymyxin B). The antifungal section will address the ramification of pharmacokinetic interactions and the need to measure drug levels. The chapter is not meant to be exhaustive and as such will not extensively address all antimicrobials or all interactions for each of these agents.


Antimicrobials Interactions Adverse reactions 


  1. 1.
    Freifeld A et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:e56–e93. On-line at: Last accessed on 12 Mar 2013
  2. 2.
    Roder BL, Nielsen SL, Magnussen P, Engquist A, Frimodt-Moller N (1993) Antibiotic usage in an intensive care unit in a Danish university hospital. J Antimicrob Chemother 32:633–642PubMedCrossRefGoogle Scholar
  3. 3.
    Lazarou J et al (1998) Incidence of adverse drug reactions in hospitalized patients: a meta analysis of prospective studies. JAMA 279:1200–1205PubMedCrossRefGoogle Scholar
  4. 4.
    Nebeker JR, Barach P, Samore M (2004) Clarifying adverse drug events: a clinician’s guide to terminology, documentation, and reporting. Ann Intern Med 140:795–801Google Scholar
  5. 5.
    Riedl M, Casillas A (2003) Adverse drug reactions: types and treatment options. Am Fam Physician 68(9):1781–1791PubMedGoogle Scholar
  6. 6.
    Gallicano K, Drusano G (2005) Introduction to drug interactions. In: Piscitelli S, Rodvold K (eds) Drug interactions in infectious diseases, 2nd edn. Humana Press, Totowa, pp 1–11Google Scholar
  7. 7.
    Executive summary of disease management of drug hypersensitivity: a practice parameter. Joint Task Force on Practice Parameters, the American Academy of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology (1999). Ann Allergy Asthma Immunol 83:665–700Google Scholar
  8. 8.
    deShazo RD, Kemp SF (1997) Allergic reactions to drugs and biologic agents. JAMA 278:1895–1906Google Scholar
  9. 9.
    Anderson JA, Adkinson NF Jr (1987) Allergic reactions to drugs and biologic agents. JAMA 258:2891–2899PubMedCrossRefGoogle Scholar
  10. 10.
    Granowitz E, Brown R (2008) Antibiotic adverse reactions and drug reactions. Crit Care Clin 24:421–442PubMedCrossRefGoogle Scholar
  11. 11.
    Gunderson BW et al (2001) What do we really know about antibiotic pharmacodynamics? Pharmacotherapy 21(11s):302s–318sPubMedCrossRefGoogle Scholar
  12. 12.
    Rodvold KA (2001) Pharmacodynamics of antiinfective therapy: taking what we know to the patient’s bedside. Pharmacotherapy 21(11 Pt 2):319S–330SPubMedCrossRefGoogle Scholar
  13. 13.
    Guay D (2005) Quinlones. In: Piscitelli S, Rodvold K (eds) Drug interactions in infectious diseases, 2nd edn. Humana Press, Totowa, pp 215–244Google Scholar
  14. 14.
    Neuhauser M, Danziger L (2005) β-lactam antibiotics. In: Piscitelli S, Rodvold K (eds) Drug interactions in infectious diseases, 2nd edn. Humana Press, Totowa, pp 255–288Google Scholar
  15. 15.
    Susla G (2005) Miscellaneous antibiotics. In: Piscitelli S, Rodvold K (eds) Drug interactions in infectious diseases, 2nd edn. Humana Press, Totowa, pp 332–389Google Scholar
  16. 16.
    Rybak M, Rotschafer J, Moellering R et al (2009) Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm 66(1):82–98PubMedCrossRefGoogle Scholar
  17. 17.
    Shoemaker M, Simou J, Roland W (2006) A review of daptomycin for injection (Cubicin) in the treatment of complicated skin and skin structure infections. Ther Clin Risk Manag 2(2):169–174PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Spratt BG, Cromie KD (1988) Penicillin-binding proteins of gram negative bacteria. Rev Infect Di s 10:699–711CrossRefGoogle Scholar
  19. 19.
    Pichichero ME (2007) Use of selected cephalosporins in pencillin-allergic patients—a paradigm shift. Diag Microbiol Infect Dis 57:13S–18SCrossRefGoogle Scholar
  20. 20.
    Saxon A et al (1984) Lack of cross-reactivity between aztreonam, a monobactam antibiotic, and penicillin in penicillin-allergic subjects. J Infect Dis 149(1):16–22PubMedCrossRefGoogle Scholar
  21. 21.
    Lee CE, Zembower TR, Fotis MA et al (2000) The incidence of antimicrobial allergies in hospitalized patients: implications regarding prescribing patterns and emerging bacterial resistance. Arch Intern Med 160:2819PubMedCrossRefGoogle Scholar
  22. 22.
    Park M, Markus P, Matesic D, Li JT (2006) Safety and effectiveness of a preoperative allergy clinic in decreasing vancomycin use in patients with a history of penicillin allergy. Ann Allergy Asthma Immunol 97:681PubMedCrossRefGoogle Scholar
  23. 23.
    Castells M (2009) Rapid desensitization for hypersensitivity reactions to medications. Immunol Allergy Clin North Am 29(3):585–606PubMedCrossRefGoogle Scholar
  24. 24.
    Kim A, Sutherland CA, Kuti JL, Nicolau DP (2007) Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion? Pharmacotherapy 27(11):1490–1497Google Scholar
  25. 25.
    Lodise TP Jr, Lomaestro B, Drusano GL (2007) Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 44(3):357–363PubMedCrossRefGoogle Scholar
  26. 26.
    Adam O, Auperin A, Wilquin F, Bourhis JH, Gachot B, Chachaty E (2004) Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies. Clin Infect Dis 38:917–920PubMedCrossRefGoogle Scholar
  27. 27.
    Ansorg R, van den Boom R, Rath P (1997) Detection of Aspergillus galactomannan antigen in foods and antibiotics. Mycoses 40:353–357PubMedCrossRefGoogle Scholar
  28. 28.
    Singh N et al. (2004) Reactivity of platelia Aspergillus galactomannan antigen with piperacillin-tazobactam: clinical implications based on achievable concentrations in serum. AAC 48:1989–1992. Google Scholar
  29. 29.
    Yahav D, Paul M, Fraser A et al (2007) Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis 7:338–348PubMedCrossRefGoogle Scholar
  30. 30.
    Leibovici L, Yahav D, Paul M (2010) Meta-analysis of a possible signal of increased mortality associated with cefepime use. Clin Infect Dis 51:1350–1351PubMedCrossRefGoogle Scholar
  31. 31.
    Kim PW et al (2010) Meta-analysis of a possible signal of increased mortality associated with cefepime use. Clin Infect Dis 51(4):381–389PubMedCrossRefGoogle Scholar
  32. 32.
    Fisher BT, Aplenc R, Localio R, Leckerman KH, Zaoutis TE (2009) Cefepime and mortality in pediatric acute myelogenous leukemia: a retrospective cohort study. Pediatr Infect Dis J 28(11):971–975PubMedCrossRefGoogle Scholar
  33. 33.
    FDA (2007) Cefepime (marketed as Maxipime). Update of ongoing safety review. Updated May 2008 Google Scholar
  34. 34.
    Zhanel GG et al (2007) Comparative review of the carbapenems. Drugs 67(7):1027–1052PubMedCrossRefGoogle Scholar
  35. 35.
    Paterson DL, Depestel DD (2009) Doripenem. Clin Infect Dis 49(2):291–298PubMedCrossRefGoogle Scholar
  36. 36.
    Asbel LE, Levison ME (200) Caphalosporins, carbapenems and monbactams. Infect Dis Clin North Am 14:435–447Google Scholar
  37. 37.
    CDC (2009) Guidance for control of infections with carbapenem-resistant or carbepenemase—producing Enterobacteriacea in acute care facilities. MMWR 58 (10):256–260Google Scholar
  38. 38.
    Wolfson JS, Hooper DC (1989) Fluoroquinolone antimicrobial agents. Clin Microbiol Rev 2(4):378–442PubMedCentralPubMedGoogle Scholar
  39. 39.
    Lipsky BA, Baker CA (1999) Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 28(2):352PubMedCrossRefGoogle Scholar
  40. 40.
    Meyer RD (1986) Risk factors and comparisons of clinical nephrotoxicity of aminoglycosides. Am J Med 80:119PubMedCrossRefGoogle Scholar
  41. 41.
    Hooper DC (1999) Mechanisms of fluoroquinolone resistance. Drug Resist Updat 2(1):38PubMedCrossRefGoogle Scholar
  42. 42.
    Neuhauser MM (2003) Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 289(7):885PubMedCrossRefGoogle Scholar
  43. 43.
    Mcdonald CL et al (2005) An epidemic, toxin gene–variant strain of Clostridium difficile. N Engl J Med 353:2433–2441PubMedCrossRefGoogle Scholar
  44. 44.
    Kumana CR, Yuen KY (1994) Parenteral aminoglycoside therapy. Selection, administration and monitoring. Drugs 47:902–913PubMedCrossRefGoogle Scholar
  45. 45.
    Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM (1999) Aminoglycosides: activity and resistance. Antimicrob Agents Chemother 43:727–737PubMedCentralPubMedGoogle Scholar
  46. 46.
    Fantin B, Ebert S, Leggett J et al (1991) Factors affecting duration of in vivo postantibiotic effect for aminoglycosides against gram-negative bacilli. J Antimicrob Chemother 27:829–836PubMedCrossRefGoogle Scholar
  47. 47.
    Humes HD (1988) Aminoglycoside nephrotoxicity. Kidney Int 33:900PubMedCrossRefGoogle Scholar
  48. 48.
    Moore RD, Smith CR, Lipsky JJ et al (1984) Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 100:352PubMedCrossRefGoogle Scholar
  49. 49.
    Aronson JK, Reynolds DJ (1992) ABC of monitoring drug therapy. Aminoglycoside antibiotics. BMJ 305(6866):1421PubMedCentralPubMedCrossRefGoogle Scholar
  50. 50.
    Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH (1997) Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother 39(6):677PubMedCrossRefGoogle Scholar
  51. 51.
    Munckhof WJ, Grayson ML, Turnidge JD (1996) A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 37:645PubMedCrossRefGoogle Scholar
  52. 52.
    Ferriols-Lisart R, Alós-Almiñana M (1996) Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. Am J Health Syst Pharm 53:1141PubMedGoogle Scholar
  53. 53.
    Dobie RA, Black FO, Pezsnecker SC, Stallings VL (2006) Hearing loss in patients with vestibulotoxic reactions to gentamicin therapy. Arch Otolaryngol Head Neck Surg 132(3):253PubMedCrossRefGoogle Scholar
  54. 54.
    Polk RE, Healy DP, Schwartz LB et al (1988) Vancomycin and the red-man syndrome: pharmacodynamics of histamine release. J Infect Dis 157:502PubMedCrossRefGoogle Scholar
  55. 55.
    Bailie GR, Neal D (1988) Vancomycin ototoxicity and nephrotoxicity. A review. Med Toxicol Adverse Drug Exp 3:376PubMedCrossRefGoogle Scholar
  56. 56.
    Moellering RC (2006) Vancomycin: a 50 year reassessment. Clin Infect Dis 42(suppl 1):S3–S4PubMedCrossRefGoogle Scholar
  57. 57.
    Healy DP, Sahai JV, Fuller SH, Polk RE (1990) Vancomycin-induced histamine release and “red man syndrome”: comparison of 1- and 2-hour infusions. Antimicrob Agents Chemother 34:550PubMedCentralPubMedCrossRefGoogle Scholar
  58. 58.
    Anne S, Middleton E Jr, Reisman RE (1994) Vancomycin anaphylaxis and successful desensitization. Ann Allergy 73:402PubMedGoogle Scholar
  59. 59.
    Moellering R (2003) Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 138:135–142PubMedCrossRefGoogle Scholar
  60. 60.
    Sakoulas G, Moise-Broder PA, Schentag J et al (2004) Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42:2398–2402PubMedCentralPubMedCrossRefGoogle Scholar
  61. 61.
    Hidayat LK, Hsu DI, Quist R et al (2006) High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 166:2138–2144PubMedCrossRefGoogle Scholar
  62. 62.
    Plosker G, Figgitt D (2005) Linezolid: a pharmcoeconomic review of its use in serious gram positive infections. Pharmcoeconomics 23(9):945–964CrossRefGoogle Scholar
  63. 63.
    Kainer M et al (2007) Response to emerging infection leading to outbreak of linezolid-resistant enterococci. EID 13(7):1024–1030Google Scholar
  64. 64.
    Perry CM, Jarvis B (2001) Linezolid: a review if its use in the management of serious gram—positive infections. Drugs 61(4):525–531PubMedCrossRefGoogle Scholar
  65. 65.
    Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH (2003) Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124:1789–1797PubMedGoogle Scholar
  66. 66.
    ATS/IDSA (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171:388–416Google Scholar
  67. 67.
    Shoemaker D, Simou J, Roland W (2006) A review of daptomycin for injection (Cubicin) in the treatment of complicated skin and skin structure. Ther Clin Risk Manag 2(2):169–174PubMedCentralPubMedCrossRefGoogle Scholar
  68. 68.
    Cubicin package insert (2008) Cubist Pharmaceuticals Inc, LexingtonGoogle Scholar
  69. 69.
    Rose W, Rybak W, Kaatz G (2007) Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. Antimicrob Chemother 60(2):334–340CrossRefGoogle Scholar
  70. 70.
    Oleson FB, Berman CL, Kirkpatrick JB et al (2000) Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 44:2948–2953PubMedCentralPubMedCrossRefGoogle Scholar
  71. 71.
    Wenzel R, Bate G, Kirkpatrick P (2005) Fresh from the pipeline: tigecycline. Nat Rev Drug Discov 4:809–810Google Scholar
  72. 72.
    Greer N (2006) Tigecycline (Tygacil): the first in the glycylcycline class of antibiotics. Proc (Bayl Univ Med Cent) 19(2):155–161Google Scholar
  73. 73.
    Hung WY et al (2009) Tigecycline-induced acute pancreatitis: case report and literature review. Int J Antimicrob Agents 34(5):486–489Google Scholar
  74. 74.
    U.S. Food and Drug Administration (2010) FDA drug safety communication: increased risk of death with tygacil (tigecycline) compared to other antibiotics used to treat similar infections, Safety announcement [09-01-2010] Last Accessed 12 Mar 2013
  75. 75.
    Zavascki A, Goldani L, Nation R (2007) Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 60(6):1206–1215PubMedCrossRefGoogle Scholar
  76. 76.
    Evans ME, Feola DJ, Rapp RP (1999) Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 33:960–967PubMedCrossRefGoogle Scholar
  77. 77.
    Falagas ME, Kasiakou SK (2006) Toxicity of polymyxins: a systematic review of the evidence fromold and recent studies. Crit Care 10:R27PubMedCentralPubMedCrossRefGoogle Scholar
  78. 78.
    Higgins DL et al (2005) Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 49(3):1127–1134PubMedCentralPubMedCrossRefGoogle Scholar
  79. 79.
    Stryjewski ME, Graham DR, Wilson SE et al (2008) Assessment of telavancin in complicated skin and skin-structure infections study. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 46(11):1683–1693PubMedCrossRefGoogle Scholar
  80. 80.
    Wilson SE, O’Riordan W, Hopkins A (2009) Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures. Am J Surg 197(6):791–796 (Epub 2008 Dec 18)PubMedCrossRefGoogle Scholar
  81. 81.
    Dunbar L, Tang D, Manausa M (2008) A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI). Ther Clin Risk Manag 4(1):235–244PubMedCentralPubMedGoogle Scholar
  82. 82.
    Daum RS (2008) Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med 359:1063–1067CrossRefGoogle Scholar
  83. 83.
    Moellering R (2008) Current treatment options for community-acquired methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 46:1032–1037PubMedCrossRefGoogle Scholar
  84. 84.
    Siberry G, Tekle T, Carroll K et al (2003) Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 37(9):1257–1260PubMedCrossRefGoogle Scholar
  85. 85.
    Centers for Disease Control and Prevention (2000) Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. MMWR Recomm Rep 49(RR-10):1–112. Available at Last accessed on 12 Mar 2013
  86. 86.
    Diasio R (1998) Sorivudine and 5-fluorouracil; a clinically significant drug–drug interaction due to inhibition of dihydropyrimidine dehydrogenase. Br J Clin Pharmacol 46(1):1–4PubMedCentralPubMedCrossRefGoogle Scholar
  87. 87.
    Balfour H (1999) Antiviral drugs. N Engl J Med 340(16):1255–1268PubMedCrossRefGoogle Scholar
  88. 88.
  89. 89.
    Mason J, Nickols H (2008) Crystalluria from acyclovir use. N Engl J Med 358(13):e14PubMedCrossRefGoogle Scholar
  90. 90.
    Trifilio S, Verma A, Mehta J (2004) Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice. Bone Marrow Transplant 33:735–739PubMedCrossRefGoogle Scholar
  91. 91.
    Crumpaker C (1996) Ganciclovir. N Engl J Med 335(10):721–729CrossRefGoogle Scholar
  92. 92.
    Gooley T et al (2010) Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 363:2091–2101PubMedCentralPubMedCrossRefGoogle Scholar
  93. 93.
    Holland GN (2008) AIDS and ophthalmology: the first quarter century. Am J Ophthalmol 145(3):397PubMedCrossRefGoogle Scholar
  94. 94.
    Ganciclovir for infusion package insert (Cytovene). Roche Labs (2006, January) Last accessed on 12 Mar 2012
  95. 95.
    Pescovitz MD, Rabkin J, Merion RM et al (2000) Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 44(10):2811–2815PubMedCentralPubMedCrossRefGoogle Scholar
  96. 96.
    Ljungman P, de La Camara R, Milpied N et al (2002) Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood 99(8):3050–3056PubMedCrossRefGoogle Scholar
  97. 97.
    Wagstaff A, Bryson H (1994) Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 48:199PubMedCrossRefGoogle Scholar
  98. 98.
    Avery RK et al (2000) A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and pre-emptive therapy. Bone Marrow Transplant 26:763–767Google Scholar
  99. 99.
    Cidofovir (Vistide®) package insert Gilead Sciences. Last accessed on 12 Mar 2013
  100. 100.
    Vandercam B, Moreau M, Goffin E et al (1999) Cidofovir-induced end-stage renal failure. Clin Infect Dis 29:948PubMedCrossRefGoogle Scholar
  101. 101.
    Meier P, Dautheville-Guibal S, Ronco PM, Rossert J (2002) Cidofovir-induced end-stage renal failure. Nephrol Dial Transplant 17:148PubMedCrossRefGoogle Scholar
  102. 102.
    Vaccher E et al (2003) Improvement of systemic human immunodeficiency virus-related non hodgkin lymphoma in the era of highly active antiretrovial therapy. Clin Infect Dis 37:1556–1564Google Scholar
  103. 103.
    Jefferson T, Demicheli V, Rivetti D et al (2006) Antivirals for influenza in healthy adults: systematic review. Lancet 367:303PubMedCrossRefGoogle Scholar
  104. 104.
    Cooper NJ, Sutton AJ, Abrams KR et al (2003) Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 326:1235PubMedCentralPubMedCrossRefGoogle Scholar
  105. 105.
    Hayden FG, Osterhaus AD, Treanor JJ et al (1997) Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med 337:874PubMedCrossRefGoogle Scholar
  106. 106.
    Nichols WG, Guthrie KA, Corey L, Boeckh M (2004) Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 39:1300PubMedCrossRefGoogle Scholar
  107. 107.
    Fiore AE, Fry A, Shay D et al (2011) Antiviral agents for the treatment and chemoprophylaxis of influenza—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Surveill Summ 60:1Google Scholar
  108. 108.
    Harper SA, Bradley JS, Englund JA et al (2009) Seasonal influenza in adults and children–diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 48:1003PubMedCrossRefGoogle Scholar
  109. 109.
    Kiatboonsri S, Kiatboonsri C, Theerawit P (2010) Fatal respiratory events caused by zanamivir nebulization. Clin Infect Dis 50:620PubMedCrossRefGoogle Scholar
  110. 110.
    Dominick L. Tamiflu (oseltamivir phosphate) Important Prescribing Information. Roche Pharmaceuticals. Revised 13 Nov 2006. Last accessed on 12 Mar 2013
  111. 111.
    Marr KA, Patterson T, Denning D (2002) Aspergillosis: pathogenesis, clinical manifestations and therapy. Infect Dis Clin North Am 16:875–894PubMedCrossRefGoogle Scholar
  112. 112.
    Marr KA, Carter RA, Boeckh M, Martin P, Corey L (2002) Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100:4358–4366PubMedCrossRefGoogle Scholar
  113. 113.
    Pfaller MA, Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20:133–163PubMedCentralPubMedCrossRefGoogle Scholar
  114. 114.
    Chamilos G, Luna M, Lewis RE et al (2006) Invasive fungal infections in patients with hematologic malignancies in a tertiary care center: an autopsy study over a 15-year period (1989–2003). Haematologica 91:986–989PubMedGoogle Scholar
  115. 115.
    Roden MM, Zaoutis TE, Buchanan WL et al (2005) Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 41:634–653PubMedCrossRefGoogle Scholar
  116. 116.
    Nucci M, Silveira MI, Spector N et al (1998) Risk factors for death among cancer patients with fungemia. Clin Infect Dis 27:107–111PubMedCrossRefGoogle Scholar
  117. 117.
    Carlson MA, Condon RE (1994) Nephrotoxicity of amphotericin B. J Am Coll Surg 179:361–381PubMedGoogle Scholar
  118. 118.
    Walsh TJ et al (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46(3):327–360PubMedCrossRefGoogle Scholar
  119. 119.
    Ellis D (2002) Amphotericin B: spectrum and resistance. J Antimicrob Chemother 49:7–10Google Scholar
  120. 120.
    Dupont B (2002) Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother 49:31–36PubMedCrossRefGoogle Scholar
  121. 121.
    Larkin J, Montero J (2003) Efficacy and safety of amphotericin B lipid complex for zygomycosis. Infect Med 20:201–206Google Scholar
  122. 122.
    Kuse ER, Chetchotisakd P, da Cunha CA et al (2007) Micafungin versus liposomal amphotericin B for candidemia and invasive candidosis: a phase III randomized double-blind trial. Lancet 369:1519–1527PubMedCrossRefGoogle Scholar
  123. 123.
    Pappas PG, Kauffman CA, Andes D et al (2009) Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48:503–535PubMedCrossRefGoogle Scholar
  124. 124.
    Wheat LJ, Freifeld AG, Kleiman MB et al (2007) Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 45:807–825PubMedCrossRefGoogle Scholar
  125. 125.
    Fielding RM, Smith PC, Wang LH et al (1991) Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob Agents Chemother 35:1208–1213PubMedCentralPubMedCrossRefGoogle Scholar
  126. 126.
    Boswell GW, Buell D, Bekersky I (1998) AmBisome (liposomal amphotericin B): a comparative review. J Clin Pharmacol 38:583–592PubMedCrossRefGoogle Scholar
  127. 127.
    Bekersky I, Fielding RM, Dressler DE et al (2002) Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother 46:828–833PubMedCentralPubMedCrossRefGoogle Scholar
  128. 128.
    Daneshmend TK, Warnock DW (1983) Clinical pharmacokinetics of systemic antifungal drugs. Clin Pharmacokinet 8:17–42PubMedCrossRefGoogle Scholar
  129. 129.
    Olsen SJ, Swedel MR, Blue B, Clark JM et al (1991) Tissue distribution of amphotericin B lipid complex in laboratory animals. J Pharmacol 43:831–835CrossRefGoogle Scholar
  130. 130.
    Atkinson A, Bennett J (1978) Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother 13(2):271–276PubMedCentralPubMedCrossRefGoogle Scholar
  131. 131.
    Nguyen MH, Peacock JE Jr, Morris AJ et al (1996) The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 100:617–623PubMedCrossRefGoogle Scholar
  132. 132.
    Martins MD, Rex JH (1996) Resistance to antifungal agents in the critical care setting: problems and perspectives. New Horiz 4:338–344PubMedGoogle Scholar
  133. 133.
    Yoon SA, Vazquez JA, Steffan PE et al (1999) High-frequency, in vitro reversible switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance. Antimicrob Agents Chemother 43:836–845PubMedCentralPubMedGoogle Scholar
  134. 134.
    Dick JD, Merz WG, Saral R (1980) Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrob Agents Chemother 18:158–163PubMedCentralPubMedCrossRefGoogle Scholar
  135. 135.
    Steinbach WJ, Perfect JR, Schell WA et al (2004) In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection. Antimicrob Agents Chemother 48:3217–3225Google Scholar
  136. 136.
    Wingard JR, White MH, Anaissie E, Raffalli J et al (2000) A randomized double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 31:1155–1163PubMedCrossRefGoogle Scholar
  137. 137.
    Goodwin SD, Cleary JD, Walawander CA et al (1995) Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin Infect Dis 20:755–761PubMedCrossRefGoogle Scholar
  138. 138.
    Girois SB, Chapuis F, Decullier E et al (2006) Adverse effects of antifungal therapies in invasive fungal infections; review and meta-analysis. Eur J Clin Microbiol Infect Dis 25:138–149PubMedCrossRefGoogle Scholar
  139. 139.
    Luber AD, Maa L, Lam M et al (1999) Risk factors for amphotercin B-induced nephrotoxicity. J Antimicrob Chemother 43:267–271Google Scholar
  140. 140.
    Deray G (2002) Amphotericin B nephrotoxicity. J Antimicrob Chemoter 49(Suppl 1):37–41CrossRefGoogle Scholar
  141. 141.
    Girois SB, Chapuis F, Decullier E et al (2006) Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. Eur J Clin Microbiol Infect Dis 25:138–149PubMedCrossRefGoogle Scholar
  142. 142.
    Barrett JP, Vardulaki KA, Conlon C et al (2003) A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 23:1295–1320CrossRefGoogle Scholar
  143. 143.
    Walsh TJ, Finberg RW, Arndt C et al (1999) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 340:764–771PubMedCrossRefGoogle Scholar
  144. 144.
    Gubbins P, McConnell S, Amsden J (2005) Antifungal agents. In: Piscitelli S, Rodvold K (eds) Drug interactions in infectious diseases, 2nd edn. Humana Press, Totowa, pp 289–337Google Scholar
  145. 145.
    Sporanox package insert (2004) Janssen Pharmaceutica, TitusvilleGoogle Scholar
  146. 146.
    Vfend package insert (2004) Roeirg, New YorkGoogle Scholar
  147. 147.
    Purkins L, Wood N, Ghahramani P et al (2003) Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety and toleration. Br J Clini Pharmacol 56(Suppl 1):37–44CrossRefGoogle Scholar
  148. 148.
    Krishna G, Parsons A, Kantesaria B et al (2007) Evaluation of pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men. Curr Med Res Opin 23:545–552PubMedCrossRefGoogle Scholar
  149. 149.
    Karthaus M, Cornely OA (2006) Second-line treatment in invasive mould infections. Mycoses 49(Suppl 1):23–26PubMedCrossRefGoogle Scholar
  150. 150.
    Owens RC Jr, Nolin TD (2006) Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis 43:1603–1611PubMedCrossRefGoogle Scholar
  151. 151.
    McLachlan AJ, Tett ES (1996) Pharmacokinetics of fluconazole in people with HIV infection: a population analysis. Br J Clin Pharmacol 41:291–298PubMedCentralPubMedCrossRefGoogle Scholar
  152. 152.
    Pfaller MA, Diekema DJ, Sheehan DJ (2006) Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 19:435–447PubMedCentralPubMedCrossRefGoogle Scholar
  153. 153.
    Pai MP, Turpin RS, Garey KW et al (2007) Association of fluconazole area under concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother 51:35–39PubMedCentralPubMedCrossRefGoogle Scholar
  154. 154.
    Baddley JW, Patel M, Bhavnani SM et al (2008) Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob Agents Chemother 52:3022–3028PubMedCentralPubMedCrossRefGoogle Scholar
  155. 155.
    Pfaller MA, Diekema DJ, Gibbs DL et al (2007) Results from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 45(6):1735–1745PubMedCentralPubMedCrossRefGoogle Scholar
  156. 156.
    Diaz M, Negroni R, Montero-Gei F et al (1992) A Pan-American 5-year study of fluconazole therapy for deep mycosis in the immunocompetent host. Pan-American Study Group. Clin Infect Dis 14(Suppl 1):S68–S76PubMedCrossRefGoogle Scholar
  157. 157.
    Barone JA, Koh JG, Bierman RH et al (1993) Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother 37:778–784Google Scholar
  158. 158.
    Prentince AG, Glasmacher A (2005) Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother 56:17–22CrossRefGoogle Scholar
  159. 159.
    Hardin TC, Graybill JR, Fetchick R et al (1988) Pharmacokinetics of intraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother 32:1310–1313PubMedCentralPubMedCrossRefGoogle Scholar
  160. 160.
    Persat F, Marzllo C, Guyotat D et al (1992) Plasma itraconazole concentrations in neutropenic patients after repeated high-dose treatment. Eur J Cancer 45:838–841CrossRefGoogle Scholar
  161. 161.
    Cartledge JD, Midgely J, Gazzard BG (1997) Itraconazole solution: higher drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis. J Clin Pathol 50:477–480PubMedCentralPubMedCrossRefGoogle Scholar
  162. 162.
    Boogaerts MA, Verhoef GE, Zachee P et al (1989) Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 32(Suppl 1):103–108PubMedGoogle Scholar
  163. 163.
    Potter M (2005) Strategies for managing systemic fungal infection and the place of itraconazole. J Antimicrob Chemoter 56 (Suppl 1): 149–154Google Scholar
  164. 164.
    Tucker RM, Haq Y, Denning DW et al (1990) Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother 26:561–566PubMedCrossRefGoogle Scholar
  165. 165.
    Ahmad SR, Singer SJ, Leissa BG (2001) Congestive heart failure associated with itraconazole. Lancet 357:1766–1767PubMedCrossRefGoogle Scholar
  166. 166.
    Sharkey PK, Rinaldi MG, Dunn JF et al (1991) High-dose itraconazole in the treatment of severe mycoses. Antimicrob Agents Chemother 35:707–713PubMedCentralPubMedCrossRefGoogle Scholar
  167. 167.
    Purkins L, Wood N, Ghahramani P et al (2002) Pharmacokinetics and safety of voriconazole following intravenous-to oral-dose escalation regimens. Antimicrob Agents Chemother 46:2546–2553PubMedCentralPubMedCrossRefGoogle Scholar
  168. 168.
    Purkins L, Wood N, Kleinermans D, Greenhalgh K et al (2003) Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol 56(Suppl 1):17–23PubMedCentralPubMedCrossRefGoogle Scholar
  169. 169.
    Dening DW, Ribaud P, Milpied N et al (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34:563–571CrossRefGoogle Scholar
  170. 170.
    Shimizu T, Ochiai H, Asell F, Shimizu H et al (2003) Bioinformatics research on inter-racial difference in drug metabolism I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CPY2C19. Drug Metab Pharmacokinet 18:48–70PubMedCrossRefGoogle Scholar
  171. 171.
    Herbrecht R, Denning DW, Metry D (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415PubMedCrossRefGoogle Scholar
  172. 172.
    Johnson LB, Kauffman CA (2003) Voriconazole: a new triazole antifungal agent. Clin Infect Dis 36:630–637PubMedCrossRefGoogle Scholar
  173. 173.
    Denning DW, Griffiths CEM (2001) Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clin Exp Dermatol 26:648–653PubMedCrossRefGoogle Scholar
  174. 174.
    Ezzet F, Wexler D, Courtney R et al (2005) Oral bioavailability of posaconazole in fasted healthy subjects comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 44:211–220PubMedCrossRefGoogle Scholar
  175. 175.
    Courtney R, Radwanski E, Lim J et al (2004) Pharmacokinetics of posaconazole co-administered with antacid in fasting and nonfasting healthy men. Antimicrob Agents Chemother 48:804–808PubMedCentralPubMedCrossRefGoogle Scholar
  176. 176.
    Ezzet F, Wexler D, Courtney R et al (2005) Oral bioavailability of posaconazole in fasted healthy subjects comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 44:211–220PubMedCrossRefGoogle Scholar
  177. 177.
    Krishna G, Sansone-Parsons A, Martinho M et al (2007) Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother 51:812–818PubMedCentralPubMedCrossRefGoogle Scholar
  178. 178.
    Krieter P, Flannery B, Musick T et al (2004) Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 48:3543–3551PubMedCentralPubMedCrossRefGoogle Scholar
  179. 179.
    Raad II, Graybill JR, Bustamante AB et al (2006) Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 42:1726–1734PubMedCrossRefGoogle Scholar
  180. 180.
    Kurtz MB, Rex JH (2001) Glucan synthase inhibitors as antifungal agents. Adv Protein Chem 56:463–475Google Scholar
  181. 181.
    Feldmesser M, Kress Y, Mednick A et al (2000) The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans. J Infect Dis 182:1791–1795PubMedCrossRefGoogle Scholar
  182. 182.
    Espinel-Ingroff A (1998) Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 36:2950–2956PubMedCentralPubMedGoogle Scholar
  183. 183.
    Denning DW (2002) Echinocandins: a new class of antifungals. J Antimicrob Chemother 49:889–891PubMedCrossRefGoogle Scholar
  184. 184.
    Balani SK, Xu X, Arison BH et al (2000) Metabolites of caspofungin acetate, a potent antifungal agent in human plasma and urine. Drug Metab Dispos 28:1274–1278PubMedGoogle Scholar
  185. 185.
    Hebert MF, Smith HE, Marbury TC et al (2005) Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol 45:1145–1152PubMedCrossRefGoogle Scholar
  186. 186.
    Stogniew M, Pu F, Henkel T et al (2003) Anidulafungin biotransformation in humans is by degradation not metabolism. Clin Microbiol Infect 9:291Google Scholar
  187. 187.
    Stone JA, Migoya EM, Hickey L et al (2004) Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob Agents Chemother 48:4306–4314PubMedCentralPubMedCrossRefGoogle Scholar
  188. 188.
    Sanz-Rodriguez C, Lopez-Duarte M, Jurado M et al (2004) Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transplant 34:13–20PubMedCrossRefGoogle Scholar
  189. 189.
    Hebert MF, Townsend RW, Austin S et al (2005) Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 45:954–960PubMedCrossRefGoogle Scholar
  190. 190.
    Greer N (2008) Doripenem (Doribax): the newest addition to the carbapenems. Proc (Bayl Univ Med Cent). 21(3):337–341Google Scholar
  191. 191.
    Tenover FC, Moellering RC Jr (2007) The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 44:1208–1215PubMedCrossRefGoogle Scholar
  192. 192.
    Rubinstein E, Cammarata S, Oliphant T, Wunderink R, Linezolid Nosocomial Pneumonia Study Group (2001) Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double blind, multicenter study. Clin Infect Dis 32:402–412PubMedCrossRefGoogle Scholar
  193. 193.
    Bellmann R, Egger P, Wiedemann CJ et al (2003) Differences in pharmacokinetics of amphotericin B lipid formulations despite clinical equivalence. Clin Infect Dis 36:1500–1501PubMedCrossRefGoogle Scholar
  194. 194.
    Cornely OA, Maertens J, Bresnik M et al (2007) Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (Ambiload trial). Clin Infect Dis 44:1289–1297PubMedCrossRefGoogle Scholar
  195. 195.
    Thomas LD, Miller GG, The AST Infectious Diseases Community of Practice (2009) Interactions between antiinfective agents and immunosuppressants. Am J Transplant 9(Suppl4):263–266CrossRefGoogle Scholar
  196. 196.
    Boogaerts MA, Maertens J, Van Der Geest R et al. (2001) Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy. Antimicrob Agents Chemoter 45:981–985Google Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Ximena Millan
    • 1
  • Victoria Muggia
    • 1
  • Belinda Ostrowsky
    • 1
  1. 1.Division of Infectious DiseasesMontefiore Medical CenterBronxUSA

Personalised recommendations